Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
announced that it is expanding its glucose monitoring technology to
include measuring glucose in the epidural space. A continuous
glucose monitoring system that takes readings in the spinal
epidural space may be integrated with existing treatments for
patients with Painful Diabetic Neuropathy (PDN).
PDN is a progressive neurological disorder that
affects approximately one-fifth of the more than 38 million
Americans with with diabetes, equating to more than 7 million
individuals.1,2 Its symptoms include pain and numbness in the feet,
legs, and hands which can significantly impact patients’ quality of
life and functional ability.3 Recently, Spinal Cord Stimulation
(SCS) technology has been indicated as a treatment option providing
significant long-term pain relief to these patients.4 A spinal cord
stimulator is an implanted device, with electrodes placed in the
epidural space, that sends low levels of electricity directly into
the spinal cord to relieve pain.5 Glucotrack’s sensor has the
potential to be integrated with existing SCS devices to measure
epidural glucose in patients with PDN who are undergoing SCS
treatment. Combining SCS and continuous glucose monitoring (CGM)
could provide several possible advantages, such as simplifying
device management for those patients.
Glucotrack has successfully completed
preclinical animal testing in an acute setting. Building on the
success of the acute studies, the Company has now initiated a
long-term animal study to assess sustained epidural glucose
monitoring performance. This is the second application of
Glucotrack’s technology for implantable continuous glucose
monitoring, in addition to its development of a long-term
Continuous Blood Glucose Monitoring (CBGM) system.
The preclinical testing compared the Glucotrack
sensor against blood glucose and a commercially available
subcutaneous CGM in an acute large animal model while varying blood
glucose levels for several hours. The results demonstrated the
Glucotrack epidural glucose values closely tracked both the blood
glucose and subcutaneous CGM values. The study was completed with
no adverse effect on the animals. A second acute study successfully
confirmed the repeatability of these results.
“We have always been committed to developing a
portfolio of innovative glucose monitoring technologies to offer
patients with diabetes more choice; today’s announcement
underscores this commitment.” said Paul V. Goode, PhD, CEO of
Glucotrack. “We are excited to pioneer the epidural glucose
monitoring space which we believe holds meaningful strategic
potential. By making disease management more intuitive and less
intrusive, Glucotrack is looking beyond traditional approaches to
improve the quality of life for millions of people with
diabetes.”
For more information about Glucotrack, visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by the Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s current and future distribution agreements; risks
relating to its ability to hire and retain qualified personnel,
including sales and distribution personnel; and the additional risk
factors described in Glucotrack’s filings with the U.S. Securities
and Exchange Commission (the “SEC”), including its Annual Report on
Form 10-K for the year ended December 31, 2023 as filed with the
SEC on March 28, 2023.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucotrackPR@icrinc.com
References:
1 Abbott CA, Malik RA, van Ross ER, Kulkarni J,
Boulton AJ. Prevalence and characteristics of painful diabetic
neuropathy in a large community-based diabetic population in the
U.K. Diabetes Care 2011;34:2220–2224.2 Centers for Disease Control
and Prevention. (2022). National Diabetes Statistics Report
website.
https://www.cdc.gov/diabetes/data/statistics-report/index.html 3
Schmader KE. Epidemiology and impact on quality of life of
postherpetic neuralgia and painful diabetic neuropathy. Clin J
Pain. 2002;18(6):350-354. doi:10.1097/00002508-200211000-00002.4
Erika A. Petersen, Thomas G. Stauss, James A. Scowcroft, Elizabeth
S. Brooks, Judith L. White, Shawn M. Sills, Kasra Amirdelfan, Maged
N. Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis G. Patterson,
Kostandinos C. Tsoulfas, Michael J. Creamer, Vincent Galan, Richard
H. Bundschu, Neel D. Mehta, Dawood Sayed, Shivanand P. Lad, David
J. DiBenedetto, Khalid A. Sethi, Johnathan H. Goree, Matthew T.
Bennett, Nathan J. Harrison, Atef F. Israel, Paul Chang, Paul W.
Wu, Charles E. Argoff, Christian E. Nasr, Rod S. Taylor, David L.
Caraway, Nagy A. Mekhail; Durability of High-Frequency 10-kHz
Spinal Cord Stimulation for Patients With Painful Diabetic
Neuropathy Refractory to Conventional Treatments: 12-Month Results
From a Randomized Controlled Trial. Diabetes Care 5 January 2022;
45 (1): e3–e6. https://doi.org/10.2337/dc21-1813 5 Dydyk AM,
Tadi P. Spinal Cord Stimulator Implant. [Updated 2023 Jul 3]. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
2024 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK555994/
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Apr 2024 to May 2024
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From May 2023 to May 2024